Genmab A/S has completed recruitment of 56 patients in the phase II study of ofatumumab (HuMax-CD20) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukaemia (CLL) in previously untreated patients. "We are pleased to complete patient enrolment in the first front line study of ofatumumab and hope to see a positive outcome for the CLL patients in this trial," said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab.
The details can be read here.
No comments:
Post a Comment